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INTRODUCTION
Since calcineurin inhibitors (CNIs), such as cyclosporine (CsA) 
and tacrolimus, were introduced in kidney transplantation 
(KT), the incidence of acute rejection has been reduced, and 
the graft survival rate early after transplantation has been im-
proved. However, despite dramatic reductions in acute rejec-
tion rates over time, long-term graft survival has not improved 
an appreciable extent.1,2 Thus, redirecting attention from early 
endpoints toward the process of long-term graft loss may be 
necessary.3 Many contributory factors for the lack of improve-
ment in late graft survival have been postulated,1 and among 
the causes of later graft failure, the leading contributor to renal 
dysfunction and eventual graft loss is chronic allograft injury 
(CAI). Seemingly, prevention of and intervention in CAI ap-
pear to be appropriate strategies for overcoming late renal graft 
failure. Meanwhile, pathologic changes in CNI nephrotoxicity 
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are almost universal at ten years, and can exacerbate CAI.4 To 
alleviate CNI nephrotoxicity, reduction and/or withdrawal of 
CNI may be necessary. 
To reduce the risk of nephrotoxicity, regimens with reduced 
CNI exposure may present a reasonable approach. Enteric-
coated mycophenolate sodium (EC-MPS) (Myfortic®, Novartis 
Pharma AG, Basel, Switzerland) is a formulation of mycophe-
nolic acid that delivers the same efficacy benefits as mycophe-
nolate mofetil (MMF), with the additional potential to reduce 
gastro-intestinal symptom burden.5,6 EC-MPS and MMF have 
been found to provide similar pharmacodynamic effects for 
inosine monophosphate dehydrogenase enzyme activity, and 
are therapeutically equivalent in de novo and maintenance 
kidney transplant recipients.7,8 The better gastro-intestinal tol-
erability of EC-MPS in comparison with MMF in maintenance 
patients has the potential to facilitate newer strategies, includ-
ing CNI minimization. To reduce CsA exposure, the appropri-
ate dosage of EC-MPS should be designed to achieve the thera-
peutic goal of immunosuppression in the early period after KT.9
According to the MORE Registry study,10 68.1% of 904 de novo 
kidney recipients received EC-MPS rather than MMF as a part 
of their immunosuppressive regimen at the time of hospital 
discharge, undertaken at 40 transplant centers in the United 
States. In addition, despite more than 50% of patients receiving 
less than the maximum recommended dose of these drugs by 
six months post-transplantation, their outcomes were excel-
lent. This suggests that a prospective trial to investigate the opti-
mum EC-MPS dose in CNI-based immunosuppression regi-
mens is warranted.
Due to the relative scarcity of previous reports on the CsA-
sparing effect of standard dose EC-MPS, this study was de-
signed to compare the efficacy and tolerability of reduced-dose 
CsA with standard-dose EC-MPS versus standard-dose CsA 
with reduced-dose EC-MPS, combined with basiliximab and 
corticosteroids, in de novo kidney recipients.
MATERIALS AND METHODS
Study design and participants
This study was designed as a prospective, multicenter (four 
transplant centers in Korea), randomized, controlled, parallel-
group trial in recipients (aged 20–65) of de novo KT. The key 
exclusion criteria included recipients of multiple organ trans-
plants or organs donated after cardiac death; donors either 
younger than 15 or older than 65 years; recipients of ABO-in-
compatible transplants; recipients with antibodies against the 
human leukocyte antigens of the donor organ; recipients’ with 
leukocyte counts of less than 2500 per μL, neutrophils less than 
1500 per μL, or platelets less than 75000 per μL; and those with 
evidence of severe liver disease.
The study was conducted in compliance with Good Clinical 
Practice guidelines. The study protocol was approved by the 
independent Institutional Review Boards of each center, and 
the procedures followed in the trial were in accordance with 
the Declaration of Helsinki. This study was registered with 
ClinicalTrials.gov (registration identifier=NCT01817322).
Immunosuppression 
The patients who were enrolled in the study after providing 
written informed consent received induction treatment with 
basiliximab (Simulect®, Novartis, Basel, Switzerland), CsA 
(Sandimmun Neoral®, Novartis, Basel, Switzerland), EC-MPS 
(Myfortic®, Novartis), and corticosteroids. Basiliximab was giv-
en just prior to transplantation and four days after transplan-
tation. CsA was given orally at a starting dose of 10 mg/kg/day 
from one day before transplantation. According to a previous 
study,11 methyl-prednisolone was injected intravenously at the 
following doses: 500 mg on the day of operation, 250 mg on the 
day after, and corticosteroids were tapered to a maintenance 
dose of more than 5 mg a day (prednisolone or equivalent). 
For the investigational group, according to previous studies 
on CsA minimization,12,13 the CsA dose was individually adjust-
ed with a target trough blood level between 100 ng/mL and 200 
ng/mL within a month after transplantation. The target blood 
trough levels of CsA were reduced to between 75 ng/mL and 
150 ng/mL until two months post-transplantation, and were 
further reduced to between 50 ng/mL and 125 ng/mL until four 
months, and then to between 50 ng/mL and 100 ng/mL until 
six months post-transplantation. The target dose of EC-MPS 
was 1440 mg/day, orally, for the investigational group through-
out the follow-up period.
For the control group, the CsA dose was individually adjust-
ed with a goal trough blood level between 200 ng/mL and 300 
ng/mL within a month after transplantation. The target blood 
trough levels of CsA were reduced to between 150 ng/mL and 
250 ng/mL until two months post-transplantation, further re-
duced to between 125 ng/mL and 200 ng/mL until four months, 
and then to between 100 ng/mL and 200 ng/mL until six months 
post-transplantation. The target dose of EC-MPS was 720 mg/
day, orally, throughout the follow-up period.
Assessments
Study visits took place on the day before transplantation (base-
line) and at one month, two months, four months, and six 
months post-transplantation. At each visit, a complete physical 
examination was performed, and laboratory values concerning 
the kidneys, liver, hematology, proteinuria, and trough levels 
of CsA were measured. Blood pressure, weight, and any prob-
lems between visits were documented. We examined renal 
function with serum creatinine level and with estimated glo-
merular filtration rates (eGFR) according to the Modification 
of Diet in Renal Disease (MDRD) formula.14 Data were record-
ed, entered into an electronic database, and re-evaluated by ex-
ternal monitors. Study monitoring and database analyses were 
performed according to Good Clinical Practice guidelines, and 
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all adverse events (AEs) and serious adverse events (SAEs) were 
documented.
Study endpoints
The primary efficacy endpoint was renal graft function, which 
was assessed with eGFR by the MDRD formula, at six months 
post-transplantation. Other prospectively defined endpoints 
included a composite variable of the incidence of efficacy fail-
ure that included biopsy-confirmed acute rejection (BCAR), 
graft loss, death, or loss to follow-up until six months post-trans-
plantation. Patients with clinical findings suggestive of acute 
rejection underwent biopsies before initiation or within 48 
hours of initiation of anti-rejection therapy, and biopsy speci-
mens were graded according to Banff criteria.15 Rejection was 
treated with corticosteroids, either with or without anti-thymo-
cyte globulin, depending on the histological grade and clinical 
course. Allograft loss was presumed to have occurred if a pa-
tient began dialysis and could not subsequently be removed 
from dialysis. Safety assessments included incidences of AEs 
and SAEs. According to a previous study,11 AE was defined as 
any untoward medical occurrence, including exacerbation of 
a pre-existing condition, in a patient in a clinical investigation 
who has received a pharmaceutical product. The event did not 
necessarily have a causal relationship with this treatment. SAE 
was defined as any AE with undesirable signs, symptoms, or 
medical conditions that met any one of the following criteria: 
1) was fatal or life-threatening, 2) resulted in persistent or sig-
nificant disability/incapacity, 3) required hospitalization or 
the prolongation of existing hospitalization, 4) was a congeni-
tal anomaly/birth defect, or 5) was an important medical 
event that might deteriorate the patient and require medical 
or surgical intervention to prevent one of the other outcomes 
listed above. Serial laboratory results and the proportion of 
patients with clinically notable abnormalities were reported.
Sample size, randomization, and statistical analysis
A sample size of 70 for each treatment group was determined 
for the primary endpoint by assuming a significance level (al-
pha) of 0.025, 90% power, with a non-inferiority margin [margin 
of equivalence of 7.5 mL/min and standard deviation (SD) of 
25.1 mL/min] with reference to a previous study16 and a 10% 
dropout rate.
Eligible individuals were randomly assigned in a 1:1 ratio to 
either the investigational group (low dose CsA+standard dose 
EC-MPS) or the control group (standard dose CsA+low dose 
EC-MPS). Randomization assignments were centrally released 
via an electronic case report form prior to transplantation. For 
the randomization of enrolled subjects, a random seed with a 
stratification factor for each research institution was generat-
ed. Block and block size were randomly assigned, and both the 
enrolled subjects and care providers involved in this study 
were blinded until randomization. 
Categorical variables were analyzed using chi-square testing 
with SPSS software, version 20.0 (SPSS Inc., Chicago, IL, USA). 
Fig. 1. Enrollment and outcomes.  CsA, cyclosporine; EC-MPS, enteric-coated mycophenolate sodium.
70 assigned to low dose CsA+standard dose EC-MPS
   69 received the allocated intervention
   1 did not receive allocated intervention
      1 protocol violation
49 completed
20 discontinued
   14 protocol violations
   4 adverse events
   2 lost follow-up
69 intention-to-treat population
49 per-protocol population
70 assigned to standard dose CsA+low dose EC-MPS
   69 received the allocated intervention
   1 did not receive allocated intervention
      1 lost follow up
50 completed
19 discontinued
   11 protocol violations
   6 adverse events
   2 lost follow-up
69 intention-to-treat population
50 per-protocol population
140 randomly assigned
140 patients assessed for eligibility
0 excluded
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All categorical values were expressed as a percentage of the 
group from which they were derived, and their p-values were 
calculated using Fisher’s exact test. Continuous variables were 
analyzed using t-test, and expressed as a mean±SD. In this 
study, p values <0.05 were considered significant.
RESULTS
Study characteristics
Patients were enrolled from July 2011 to February 2013. Fig. 1 
shows the profile of this clinical trial. Of 140 randomized pa-
tients, 138 (69 in the investigational group and 69 in the con-
trol group) were provided with at least one dose of the study 
drug after transplantation, and comprised the intention-to-
treat (ITT) population. Ninety-nine (49 in the investigational 
group and 50 in the control group) patients completed the 
study follow-up and completed the study drug; they comprised 
the per-protocol (PP) population. The main reasons for discon-
tinuation before the end of the study at six months post-trans-
plant were protocol violation, rejection, unsatisfactory thera-
peutic effects, and loss at follow-up (Fig. 1). The characteristics 
of the patients and their donors were similar between the 
groups, as displayed in Table 1. 
Table 1. Baseline Demographics and Clinical Characteristics (ITT Population)*
Group
Low dose CsA+standard dose EC-MPS
 (n=69)
 Standard dose CsA+low dose EC-MPS 
(n=69)
p value
Recipient variables
Age, yr 43.8±10.5 45.4±11.9 0.391
Male recipient, n (%) 38 (55.1) 47 (68.1) 0.161
Weight, kg 61.2±11.5 65.2±13.8 0.065
Height, cm 165.0±8.4 165.6±7.7 0.688
Kidney disease, n (%) 0.989
Hypertension 14 (20.3) 19 (27.5)
Glomerulonephritis 15 (21.7) 16 (23.2)
Diabetes 10 (14.5) 7 (10.1)
Polycystic kidney disease 3 (4.4) 2 (2.9)
Others 5 (7.2) 5 (7.3)
Unknown 22 (31.9) 20 (29.0)
Types of dialysis, n (%) 0.956
Hemodialysis 53 (76.8) 51 (73.9)
CAPD 10 (14.5) 12 (17.4)
Pre-emptive 6 (8.7) 6 (8.7)
Donor variables
Age, yr 41.1±11.8 43.0±12.9 0.368
Male donor, n (%) 42 (60.9) 38 (55.1) 0.605
Type of donation, n (%) 0.839
Living 40 (58.0) 36 (52.2)
Deceased 29 (42.0) 33 (47.8)
Degree of HLA-A mismatch 0.735
0 17 (24.6) 14 (20.3)
1 40 (58.0) 45 (65.2)
2 12 (17.4) 10 (14.5)
Degree of HLA-B mismatch 0.374
0 10 (14.5) 5 (7.2)
1 30 (43.5) 30 (43.5)
2 29 (42.0) 34 (49.3)
Degree of HLA-DR mismatch 0.144
0 12 (17.4) 11 (15.9)
1 45 (65.2) 36 (52.2)
2 12 (17.4) 22 (31.9)
ITT, intention-to-treat; CsA, cyclosporine; EC-MPS, enteric-coated mycophenolate sodium; CAPD, continuous ambulatory peritoneal dialysis; HLA, human leuko-
cyte antigen.
*Continuous variables are expressed as the mean±standard deviation and their p-values are calculated with t-test. Categorical variables are expressed as num-
ber (%) and their p-values are calculated with Fisher’s exact test.
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Cyclosporine exposure and study drug compliance
The mean blood trough levels and doses of CsA at one, two, 
four, and six months post-transplantation are shown in Table 2. 
The mean blood trough levels of CsA in the investigational 
group at one, two, four, and six months post-transplantation 
were 178.0±69.3, 146.0±56.5, 115.3±46.7, and 103.5±38.9 ng/
mL, respectively. Those in the control group were 221.2±68.8, 
189.4±78.4, 144.9±43.0, and 142.9±44.8 ng/mL, respectively. Re-
flecting lower CsA exposure, CsA trough levels at one, two, four, 
and six months were significantly lower (p<0.05) in the inves-
tigational group than in the control group. 
Overall compliance with the study drug (EC-MPS) was 96.0% 
in the investigational group and 97.7% in the control group.
Efficacy and allograft function
In the ITT population, the mean eGFR at one month post-
transplantation was 64.6±21.0 mL/min/1.73 m2 in the investi-
gational group, compared to 58.7±18.2 mL/min/1.73 m2 in the 
control group (p=0.091). At two months post-transplantation, 
it was 62.2±15.9 mL/min/1.73 m2 in the investigational group, 
compared to 57.6±15.2 mL/min/1.73 m2 in the control group 
(p=0.118), and at four months post-transplantation, it was 
61.2±14.7 mL/min/1.73 m2 in the investigational group, com-
pared to 57.5±13.2 mL/min/1.73 m2 in the control group (p= 
0.173). At six months post-transplantation, it was 62.3±17.3 mL/
min/1.73 m2 in the investigational group, compared to 58.6±14.4 
mL/min/1.73 m2 in the control group (p=0.237), as displayed 
in Fig. 2. By the non-inferiority test, the mean eGFR of the in-
vestigational group at six months post-transplantation was sig-
nificantly non-inferior to that of the control group (the confi-
dence interval was between 57.5 mL/min/1.73 m2 and 67.2 
mL/min/1.73 m2, p<0.001).
In the PP population, the mean eGFR at one month post-
transplantation was 65.7±21.1 mL/min/1.73 m2 in the investi-
Table 2. The Blood Trough Level and Dose of CsA (PP Population)*
Group
Low dose CsA+standard dose EC-MPS
(n=49)
 Standard dose CsA+low dose EC-MPS 
(n=50)
p value
Blood trough level, ng/mL   
Month 1 178.0±69.3 221.2±68.8 0.002
Month 2 146.0±56.5 189.4±78.4 0.002
Month 4 115.3±46.7 144.9±43.0  0.001
Month 6 103.5±38.9 142.9±44.8 <0.001
Dose, mg/day
Month 1 248.5±81.7 273.0±71.8 0.116
Month 2 200.5±64.4 228.0±75.5 0.055
Month 4 167.2±55.1 194.5±63.1 0.024
Month 6 156.0±46.2 195.5±60.8 <0.001
PP, per-protocol; CsA, cyclosporine; EC-MPS, enteric-coated mycophenolate sodium.
*Continuous variables were expressed as the mean±standard deviation, and their p-values were calculated with t-test. 
Fig. 2. Graft renal function measured by estimated glomerular filtration rates (Modification of Diet in Renal Disease) (ITT and PP population). ITT, intention-
to-treat; PP, per-protocol; CsA, cyclosporine; EC-MPS, enteric-coated mycophenolate sodium.
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gational group, compared to 60.0±17.5 mL/min/1.73 m2 in the 
control group (p=0.148). At two months post-transplantation, 
it was 62.8±16.6 mL/min/1.73 m2 in the investigational group, 
compared to 58.5±15.2 mL/min/1.73 m2 in the control group 
(p=0.176), and at four months post-transplantation, it was 61.8± 
15.2 mL/min/1.73 m2 in the investigational group, compared 
to 57.3±13.3 mL/min/1.73 m2 in the control group (p=0.123). 
Finally, at six months post-transplantation, it was 62.3±17.7 
mL/min/1.73 m2 in the investigational group, compared to 
58.6±14.4 mL/min/1.73 m2 in the control group (p=0.246), as 
displayed in Fig. 2. By the non-inferiority test, the mean eGFR 
of the investigational group at six months post-transplantation 
was significantly non-inferior to that of the control group (con-
fidence interval: 57.3 mL/min/1.73 m2 and 67.4 mL/min/1.73 m2, 
p<0.001). 
In the ITT population, the overall incidence of treated BCAR 
within six months post-transplantation in the investigational 
group was 8.7%, compared to 18.8% in the control group (p= 
0.137). One graft loss in the control group and no patient deaths 
in either group were reported. 
Safety
Among the 138 patients in the ITT population, 122 (88.4%) ex-
perienced an AE. Sixty-two (89.9%) of the 69 patients in the 
investigational group and 60 (87.04%) of the 69 patients in the 
control group reported an AE during the study period. The in-
cidence of AE was not significant between the groups (p=0.431), 
and the incidence of SAEs, severe AE, and AE leading to study 
drug discontinuation were not statistically significant (p=0.377, 
0.699, and 0.247, respectively). A total of 366 AEs were report-
ed: 177 in the investigational group and 189 in the control group. 
The most frequently reported AEs by system organ class were 
infections (22.0% in the investigation group and 17.5% in the 
control group, p=0.343), gastrointestinal disorders (13.0% in 
the investigation group and 16.4% in the control group, p= 
0.456), and metabolism and nutrition disorders (9.0% in the in-
vestigation group and 9.0% in the control group, p=0.809). The 
incidence of AEs by system organ class was generally similar 
between the groups and the majority of AEs were mild-to-
moderate in severity (Table 3).
Laboratory values, including white blood cell count, hemo-
globin, platelet count, cholesterol, and transaminase profiles, 
at one month and six months post-transplantation were com-
parable between the groups (Table 4).
Table 3. AEs Over 6 Months of Treatment (ITT Population)*
Group
Low dose CsA+standard dose EC-MPS
 (n=69)
Standard dose CsA+low dose EC-MPS 
(n=69)
No. of patients with any AE, n (%) 62 (89.9) 60 (87.0)
No. of patients with SAEs, n (%) 22 (31.9) 32 (46.4)
No. of patients with severe AEs, n (%) 10 (14.5) 9 (13.9)
No. of patients with AEs leading to study discontinuation, n (%) 4 (5.8) 6 (8.7)
No. of AEs reported by system organ class, n (%) 177 (100)  189 (100)
Infections 39 (22.0) 33 (17.5)
Gastrointestinal disorders 23 (13.0) 31 (16.4)
Metabolism and nutrition disorders 16 (9.1) 17 (9.0)
Skin and subcutaneous tissue disorders 11 (6.2) 10 (5.3)
Musculoskeletal and connective tissue disorders 6 (3.4) 2 (1.1)
Investigations 15 (8.5) 20 (10.6)
Respiratory, thoracic and mediastinal disorders 12 (6.8) 8 (4.2)
General disorders and administrations site conditions 0 (0.0) 5 (2.6)
Nervous system disorders 2 (1.1) 0 (0.0)
Renal and urinary disorders 8 (4.5) 9 (4.8)
Eye disorders 2 (1.1) 1 (0.5)
Injury, poisoning and procedural complications 8 (4.5) 22 (11.6)
Blood and lymphatic system disorders 11 (6.2) 7 (3.7)
Vascular disorders 4 (2.3) 7 (3.7)
Psychiatric disorders 10 (5.7) 8 (4.2)
Cardiac disorders 3 (1.7) 2 (1.1)
Reproductive system and breast disorders 2 (1.1) 2 (1.1)
Endocrine disorders 5 (2.8) 4 (2.1)
Hepatobiliary disorders 0 (0.0) 1 (0.5)
ITT, intention-to-treat; AE, adverse event; SAE, serious adverse event; CsA, cyclosporine; EC-MPS, enteric-coated mycophenolate sodium.
*Categorical variables were expressed as number (%).
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DISCUSSION
Our experience with using standard dose EC-MPS in combi-
nation with reduced-exposure CsA and steroids in de novo KT 
provides additional strong evidence that this strategy is safe 
and efficacious. The allograft function of the investigational 
group (low dose CsA with standard dose EC-MPS) was non-in-
ferior to that of the control group (standard dose CsA with low 
dose EC-MPS). This result suggests that standard dose EC-
MPS can elicit CNI minimization and potentially reduce CNI 
nephrotoxicity, preserving renal function. Given the immuno-
suppression protocol, fewer side effects that are usually asso-
ciated with the standard dose EC-MPS were reported. In terms 
of the incidence of acute rejection, standard dose EC-MPS 
combined with reduced-exposure CsA revealed as low an in-
cidence of acute rejection as that of standard dose CsA with 
low dose EC-MPS. According to this result, the standard dose 
of EC-MPS combined with low-dose CsA can be a powerful 
and efficacious combination for preventing acute rejection. A 
previous study also reported that reduced CsA dose (target 
trough levels of 50–100 ng/mL) with MMF was efficient at pre-
venting acute rejection and preserving kidney function in de 
novo KT.12 Another previous randomized trial reported that 
there was significant improvement in eGFR in the low-expo-
sure CsA group, compared to the standard-exposure group.17 
Several strategies exist to spare CNIs, including the use of 
agents, such as MMF, EC-MPS, sirolimus, everolimus, or belata-
cept. Mycophenolic acid derivatives have been used success-
fully to facilitate CNI minimization, improving short-term renal 
function after KT. Although MMF is known to be therapeuti-
cally equivalent to EC-MPS in de novo renal transplantation,18 
gastrointestinal symptoms have been more frequently report-
ed for MMF.8,19 A previous study reported that histologic chang-
es in MMF-related enterocolitis included apoptosis, dilated 
crypts lined by attenuated epithelial cells, crypt loss, clusters of 
residual endocrine cells, and edematous lamina propria with 
sparse inflammatory cells.20 In the literature, clinical studies 
reporting on the CsA-sparing effect of EC-MPS are relatively 
fewer than those of MMF. 
A recent study demonstrated that an intensified dose (2160 
mg/day) of EC-MPS facilitated CsA sparing early after KT.21 
However, AEs with a suspected relationship to the study drug 
were reported in 69.8% and 50.8% of patients in the intensi-
fied and standard regimen groups, respectively (p=0.032), in 
another report.22 Similar to a recent report,23 we investigated 
the CsA-sparing effect of standard dose EC-MPS in de novo 
kidney transplant patients. Unlike the aforementioned study, 
our study results suggested that low dose CsA with standard 
dose EC-MPS versus standard dose CsA with low dose EC-
MPS is therapeutically equivalent in de novo renal transplant 
recipients.
To minimize or avoid CNI nephrotoxicity, the minimization 
or total avoidance of CNI exposure should be emphasized. The 
role of EC-MPS has been examined in protocols minimizing 
CsA.24,25 In these studies, investigations into the use of EC-MPS 
with both standard- and low-dose CsA have demonstrated 
Table 4. Laboratory Values at 1 Month and 6 Months Post-Transplantation (ITT Population)*
Group
Low dose CsA+standard dose EC-MPS
 (n=69)
 Standard dose CsA+low dose EC-MPS 
(n=69)
p value
WBC count ( ×1000/mm3)
1 month 7.87±2.40 7.78±2.69 0.848
6 months  6.67±1.80  7.21±1.94 0.107
Hemoglobin (g/dL)
1 month 11.8±1.4 11.4±1.6 0.152
6 months 13.0±1.7 13.1±1.9 0.757
Platelet count (×1000/mm3)
1 month 213.51±50.23 213.74±66.54 0.982
6 months 225.88±55.89 219.96±46.32 0.566
Cholesterol (mg/dL)
1 month 222.6±48.1 208.1±39.7 0.065
6 months 201.5±38.1 200.6±36.1 0.900
AST (U/L)
1 month 18.5±6.2 18.3±5.2 0.322
6 months 18.9±5.9 19.5±5.1 0.635
ALT (U/L)
1 month 26.1±24.8 28.8±24.8 0.299
6 months 19.6±8.4 23.2±13.8 0.144
ITT, intention-to-treat; CsA, cyclosporine; EC-MPS, enteric-coated mycophenolate sodium; WBC, white blood cell; AST, aspartic acid transaminase; ALT, alanine 
transaminase.
*Continuous variables are expressed as the mean±standard deviation, and their p-values are calculated with t-test.
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excellent efficacy in both de novo and maintenance patients. 
Given that most transplant centers, even in Korea, prefer to 
reduce the dose of EC-MPS with tacrolimus,10 our results pro-
vide strong evidence that reducing CsA with standard-dose 
EC-MPS could be therapeutically equivalent and preferable to 
reducing EC-MPS with a standard dose of CsA, not only in 
terms of efficacy but also for the safety of these immunosup-
pressive regimens.
Our study has several limitations. First are the relatively short 
follow-up time and small study population. Second, we only 
showed the non-inferiority of the study group (low-dose CsA 
with standard dose EC-MPS). Although, previous studies have 
outlined the efficacy and safety of low-dose CsA,12,17 recently, 
tacrolimus has been primarily used for CNI in KT.11 Therefore, 
we believe further studies focusing on optimal CNI-sparing 
regimes with MMF in de novo KT are needed. 
In conclusion, the results of this study provide evidence that 
1) CsA minimization using standard-dose EC-MPS keeps the 
incidence of acute rejection and additional risks as low as con-
ventional immunosuppression and that 2) this facilitates the 
minimization of CsA exposure and provides therapeutic equiv-
alences in terms of the incidence of acute rejection, renal graft 
function, and safety issues.
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